Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial

Subcutaneous delivery of monoclonal antibodies: How do we get there?

(2018) Margarida Viola et al.   JOURNAL OF CONTROLLED RELEASE

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability

(2017) Andrea Becciolini et al.   Drug Design Development and Therapy

CT-P13: design, development, and place in therapy

(2017) Tommaso Gabbani et al.   Drug Design Development and Therapy

Comparative effectiveness of the biosimilar CT-P13

(2017) Dae Hyun Yoo   Journal of Comparative Effectiveness Research

Subcutaneous Administration of Monoclonal Antibodies in Oncology

(2014) C. Jackisch et al.   GEBURTSHILFE UND FRAUENHEILKUNDE

Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study

(2014) Tsutomu Takeuchi et al.   Modern Rheumatology

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES